IQVIA Holdings Inc. (IQV)

NYSE: IQV · USD

$279

+7.09 (+2.6%)· Recorded snapshot

영어 원본으로 대체KO

번역하는 동안 영어 원본을 표시 중

이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

StockMarketAgent Research · Analyzed 2026-10-03

Our latest published analysis: IQV rated Reduce

IQVIA Holdings Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$215 / share

Potential value

$256 / share

Upside to FV

-16.7%

from $279

Moat

7.8/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$42.5B
Revenue (ttm)	17.3B
Net income (ttm)	1.4B
EPS (ttm)	$8.25
Shares out	164.8M
P/E (trailing)	33.8x
P/E (forward)	18.4x
Volume	1,396,426
Beta	1.17

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 17.3B
Net income (ttm): 1.4B
EPS (ttm): $8.25
P/E (trailing): 33.8x
P/E (forward): 18.4x
Market cap: $42.5B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$13.87B	$14.41B	$14.98B	$15.41B	$16.31B	+4.1%
Gross profit	$4.64B	$5.03B	$5.24B	$5.38B	$4.29B	-2.0%
Operating income	$1.39B	$1.80B	$1.98B	$2.20B	$2.18B	+11.9%
Net income	$966.0M	$1.09B	$1.36B	$1.37B	$1.36B	+8.9%
EPS (diluted)	$4.95	$5.72	$7.29	$7.49	$7.84	+12.2%
EBITDA	$2.77B	$2.91B	$3.26B	$3.45B	$3.46B	+5.8%
R&D	—	—	—	—	—	—
SG&A	$1.96B	$2.07B	$2.05B	$1.99B	$2.00B	+0.4%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	매도
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	매도
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	적극 매수
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	매도
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	비중 축소
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	비중 축소

Base and Bull scenarios

Base65%

Price target

$215.19

-16.7% from spot

The Base scenario reflects the modal operating path where clinical trial execution compounds at steady mid-single-digit rates, supported by multi-year trial commitments across global pharmaceutical sponsors. Technology and Analytics Solutions delivers predictable recurring revenue from proprietary syndicated prescription databases and enterprise commercial software. Operating margins expand modestly as high-margin data products gradually offset clinical site coordinator wage pressures. The house Fair value $215.19 corresponds to this trajectory, indicating -16.7% implied return from the share price $258.21 with an assigned probability of 65.0%.

Revenue compounds at mid-single-digit rates across the forecast horizon, matching consensus expectations for FY2026 and FY2027
Operating margin expands modestly from historical baselines as software delivery offsets clinical site personnel inflation
Free cash flow conversion remains solid, supporting disciplined share repurchases and orderly debt service

Bull15%

Price target

$256.27

-0.8% from spot

Under the Bull scenario, robust biopharmaceutical venture funding accelerates Phase II and Phase III trial starts, driving double-digit net bookings in clinical research. Simultaneously, rapid adoption of artificial intelligence tools and real-world evidence platforms in commercial analytics accelerates revenue expansion and pushes operating margins toward the upper end of historical ranges. Robust cash generation enables sustained share count reduction while debt is steadily paid down. The stock reaches Potential value $256.27 under this outcome, representing -0.8% return from the share price $258.21 with a probability of 15.0%.

Consolidated revenue growth accelerates above historical averages driven by strong biopharma clinical trial commitments
Operating margin expands toward upper historical levels supported by favorable software product mix in technology solutions
Operating cash flow comfortably covers capital expenditures, funding both share repurchases and balance sheet deleveraging

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($215.19). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
8.7%	$224	$227	$230	$233	$237
9.2%	$216	$218	$221	$224	$227
9.7%	$208	$210	$215	$215	$218
10.2%	$202	$204	$206	$208	$210
10.7%	$196	$198	$199	$201	$203

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E18.4

P25 n/aP50 n/aP75 n/a

Trailing P/E32.3

P25 n/aP50 n/aP75 n/a

ROE21.4

P25 n/aP50 n/aP75 n/a

ROIC9.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All IQV indicators

Market & fundamental data

Available fields

270

Groups with data

Currency

USD

Showing 270 of 270 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001478242
Company name	IQVIA Holdings Inc.
Country	United States
Country code	US
CUSIP number	46266C105
Earnings date	2026-10-27
Earnings time	bmo
Employees	94,000
Employees change	4,000
Employees growth	4.44%
Enterprise value	$59.8B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	1982
In index	SP500
Industry	Diagnostics & Research
IPO date	2013-05-09
Is primary listing	Yes
Is SPAC	No
ISIN number	US46266C1053
Last 10-K release date	2026-02-17
Last earnings date	2026-10-27
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$45.9B
Market cap category	Large-Cap
Next earnings date	2027-02-04
Options	Yes
Price	$278.63
Price currency	USD
Sector	Healthcare
SIC code	8731
Stock price date	2026-10-28
Symbol	IQV
U.S. state	North Carolina
Website	https://www.iqvia.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	21.75x
Average P/E ratio (10Y)	76.79x
Average P/E ratio (3Y)	26.95x
Average P/E ratio (5Y)	31.22x
Earnings yield	2.96%
EV/Earnings	42.7x
EV/EBIT	24.76x
EV/EBITDA	19.09x
EV/FCF	28.63x
EV/Sales	3.44x
FCF / EV yield	3.49%
FCF yield	4.56%
Forward EV/Sales	3.27x
Forward P/E	20.07x
Forward P/S	2.5x
Graham number	86.63668
Graham upside	-68.71%
Industry forward P/E	31.53x
Industry P/E	51.31x
Lynch fair value	$104.77
Lynch upside	-62.16%
P/(FCF - SBC) ratio	25.69x
P/(OCF - SBC) ratio	18.75x
P/B ratio	6.72x
P/E ratio	33.75x
P/FCF ratio	21.95x
P/OCF ratio	16.68x
P/S ratio	2.64x
PEG ratio	1.75x
Price/EBITDA ratio	14.63x
Sector forward P/E	23.65x
Sector P/E	50.36x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	13.89%
EBITDA margin	18.01%
Effective tax rate	15.37%
FCF margin	12.01%
Gross margin	33.07%
Operating margin	13.89%
Pretax margin	9.55%
Profit margin	8.05%
Profit per employee	$14,830
Profitable quarters	25
Profitable years	16
Revenue per employee	$184,160
ROA	5.08%
ROA (5Y)	4.73%
ROCE	10.59%
ROE	21.39%
ROE (5Y)	20.22%
ROIC	9.89%
ROIC (5Y)	9.33%
SBC / revenue	1.75%
Tax / revenue	1.47%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	13.03%
EPS growth (Q)	8.81%
EPS growth (QoQ)	37.25%
EPS growth 10Y	9.76%
EPS growth 3Y	11.51%
EPS growth 5Y	16.01%
EPS growth quarters	1
EPS growth years	6
FCF growth	-5.97%
FCF growth (Q)	-13.6%
FCF growth (QoQ)	85.28%
FCF growth 3Y	16.32%
FCF growth 5Y	-2.57%
Gross profit growth	6.55%
Gross profit growth (Q)	9.1%
Gross profit growth 3Y	3.38%
Gross profit growth 5Y	4.95%
Net income growth	8.65%
Net income growth (Q)	5.74%
Net income growth (QoQ)	36.72%
Net income growth 3Y	7.7%
Net income growth 5Y	12.69%
Net income growth quarters	1
Net income growth years	0
OCF growth	-2.43%
OCF growth (Q)	-9.14%
OCF growth (QoQ)	47.85%
OCF growth 10Y	16.01%
OCF growth 3Y	11.72%
OCF growth 5Y	-1.83%
Operating income growth	6%
Operating income growth (Q)	6.11%
Operating income growth 3Y	6.9%
Operating income growth 5Y	13.74%
Revenue growth	8.85%
Revenue growth (Q)	8%
Revenue growth (QoQ)	1.37%
Revenue growth 10Y	14.32%
Revenue growth 3Y	5.23%
Revenue growth 5Y	5.04%
Revenue growth quarters	25
Revenue growth years	15

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-657M
Depreciation and amortization	$714M
EBIT	$2.4B
EBITDA	$3.1B
EPS	$8.25
FCF per share	$12.62
Financing cash flow	$-34M
Free cash flow	$2.1B
Free cash flow minus SBC	$1.8B
Gross profit	$5.7B
Income taxes	$254M
Investing cash flow	$-2.2B
Net borrowing	$1.3B
Net cash flow	$435M
Net income	$1.4B
Operating cash flow minus SBC	$2.4B
Operating income	$2.4B
Revenue	$17.3B
Stock-based compensation	$303M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.04
Book value per share	$40.41
Debt / EBITDA	4.97
Debt / equity	2.4
Debt / FCF	7.85
Goodwill	$16.9B
Interest coverage	3.06
Long-term assets	$24B
Long-term liabilities	$15.9B
Net cash (debt)	$-13.9B
Net cash / market cap	-30.45%
Net debt / EBITDA	4.46
Net debt / equity	2.05
Net debt / FCF	6.68
Piotroski F-Score	6
Property, plant and equipment	$847M
Shareholders' equity	$6.8B
Tangible book value	$-15B
Tangible book value per share	$-90.89
Total assets	$30.5B
Total cash	$2.4B
Total debt	$16.3B
Total liabilities	$23.7B
WACC	8.96%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.58
Current assets	$6.5B
Current liabilities	$7.8B
Current ratio	0.83
Net working capital	$-2.5B
Quick ratio	0.74
Working capital	$-1.3B
Working capital turnover	-8.98

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	3.88%
Dividend yield	0%
Shareholder yield	3.88%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	286.45%
10Y return CAGR	14.48%
10Y total return	286.45%
150-day SMA	$215.23
1D price change	2.61%
1M price change	3.06%
1M total return	3.06%
1W price change	0.72%
1W total return	0.72%
1Y price change	28.15%
1Y return CAGR	28.17%
1Y total return	28.15%
20-day SMA	$266.83
200-day SMA	$209.22
3M price change	30.68%
3M total return	30.68%
3Y price change	54.85%
3Y return CAGR	15.69%
3Y total return	54.85%
50-day SMA	$265.34
50-day SMA vs 200-day SMA	50over200
52-week high	$284.50
52-week high date	2026-10-27
52-week low	$154.50
52-week low date	2026-04-30
5Y price change	9.57%
5Y return CAGR	1.85%
5Y total return	9.57%
6M price change	70.06%
6M total return	70.06%
All-time high	$285.61
All-time high date	2021-12-30
All-time low	$40.10
All-time low date	2013-10-31
Average true range (ATR)	$9.04
Average volume	1.3M
Beta (1Y)	0.77
Beta (2Y)	0.89
Beta (5Y)	1.17
Change from 52-week high	-2.06%
Change from 52-week low	80.34%
Change from all-time high	-2.44%
Change from all-time low	594.84%
Change from open	2.9%
Day's gap	-0.29%
Dollar volume	$389.1M
High price	$282.04
Low price	$270.77
Monthly RSI	64.84
Open price	$270.77
Position in 52-week range	69.74%
Premarket change	-2.2%
Premarket close	$271.55
Premarket price	$265.58
Previous close	$271.55
Price vs 150-day SMA	29.46%
Price vs 20-day SMA	4.42%
Price vs 200-day SMA	33.18%
Price vs 50-day SMA	5.01%
Relative volume	1.06
RSI	61.44
Sharpe ratio	0.72
Sharpe ratio (3Y)	0.45
Sharpe ratio (5Y)	0.12
Sortino ratio	1.24
Sortino ratio (3Y)	0.87
Sortino ratio (5Y)	0.35
Volume	1.4M
Weekly RSI	71.57
YTD price change	23.61%
YTD total return	23.61%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	156.3M
Float percentage	94.81%
Shares change (QoQ)	-0.18%
Shares change (YoY)	-3.88%
Shares held by insiders	0.97%
Shares held by institutions	98.3%
Shares outstanding	164.8M
Short % of float	1.91%
Short % of shares	1.82%
Short ratio	1.9 days

Deeper analysis on IQV

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this IQV report

What is the latest published IQV stock rating?

IQVIA Holdings Inc. is shown with Reduce in the latest published report, analyzed 2026-10-03. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full IQV analysis?

The full latest published report, analyzed 2026-10-03, lives at /stocks/IQV/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for IQV?

The latest published report analyzed 2026-10-03 gives IQV a fair value of USD 215 and a potential value of USD 256. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the IQV page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-03). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

ReduceIQV · Fair value $215-16.7%

Read full analysis →

IQVIA Holdings Inc. (IQV)

Our latest published analysis: IQV rated Reduce

Price

Financial snapshot

Fair-value bridge

Latest news · IQV

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All IQV indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on IQV

Frequently asked questions

등급 이력

Category	Score	Reading
Valuation	3.0
Management	6.5
Balance Sheet	1.5
Profitability	6.0
Revenue Growth	6.0
Risk Assessment	2.5
Competitive Moat	7.8
Earnings Quality	7.5
Capital Efficiency	5.5